← Back to Patent Explorer
US4512992A Expired / Lapsed US ⏱️ 0.0 years remaining

Treatment with dialkoxy pyridopyrimidine compounds

Assignee: SmithKline Beecham Corp
•
Filing: 1981-02-06
•
Granted: 1985-04-23
•
Expires: 2001-02-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This application is directed to treatment of psoriasis with a pyrido pyrimidine compound such as 2,4-diamino-6-(3,4-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.

Inventors

  • 👤 David S. Duch
  • 👤 Charles A. Nichol
  • 👤 Carl W. Sigel

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 13:17
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 49 words
A method of treating psoriasis in a mammal suffering from psoriasis comprising the administration of a non-toxic, effective antipsoriasis amount of a compound of formula (II): ##STR25## wherein R and R' are lower (C 1 -C 6 ) alkyl, or pharmaceutically acceptable acid addition salt thereof to said mammal.
Claim 2
Independent Claim 49 words
A method of treating psoriasis in a mammal suffering from psoriasis comprising the administration of a non-toxic, effective antipsoriasis amount of a compound of formula (II): ##STR25## wherein R and R' are lower (C 1 -C 6 ) alkyl, or pharmaceutically acceptable acid addition salt thereof to said mammal.
Claim 3
Dependent Claim 12 words
A method according to claim 1 in which said compound is 2,4-diamino-6-(3,4-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.
Claim 4
Dependent Claim 20 words
The method of claim 1 or 2 in which the compound or salt is administered in a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim 22 words
The method of claim 1 or 2 in which the compound or salt is administered as a part of a topical formulation.
Claim 6
Dependent Claim 37 words
The method of claim 1 or 2 in which the compound or salt is administered as a part of a topical formulation in which the compound or salt is at a concentration of 0.05 to 2% w/w.
Claim 7
Dependent Claim 24 words
The method of claim 1 or 2 in which the compound or salt is administered as part of an oral preparation or parenteral preparation.
Claim 8
Dependent Claim 30 words
The method of claim 1 or 2 in which the compound or salt is administered in a pharmaceutically acceptable carrier in a form suitable for topical, parenteral or oral administration.
Claim 9
Dependent Claim 20 words
The method of claim 7 in which the amount of the compound or salt is 50 mg to 1 gram.

References Cited (Backward Citations)

GB913710A Cited
GB970583A Cited
US3322765A Cited
GB1084103A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-04-22 1988-10-22 1989-04-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-04-22 1992-10-22 1993-04-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-04-22 1996-10-22 1997-04-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag